Please login to the form below

Not currently logged in
Email:
Password:

Mirna Therapeutics appoints new executive vice president

Miguel Barbosa willalso serve as chief scientific officer

Mirna Therapeutics has appointed Dr Miguel Barbosa as executive vice president and chief scientific officer.

Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics.

Barbosa joined the company with 20 years of biopharmaceutical research discovery experience and for the past decade has served in senior leadership roles at Johnson & Johnson subsidiaries.

Paul Lammers, Mirna's president and chief executive officer, said: “We are pleased to welcome Miguel to the role of chief scientific officer.

As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel's expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”

30th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics